Details

Autor(en) / Beteiligte

• Bansode, Avinash H.
• Damuka, Naresh
• Bashetti, Nagaraju
• Gollapelli, Krishna Kumar
• Krizan, Ivan
• Bhoopal, Bhuvanachandra
• Miller, Mack
• JV, Shanmukha Kumar
• Whitlow, Christopher T.
• McClain, Donald
• Ma, Tao
• Jorgensen, Matthew J.
• Solingapuram Sai, Kiran Kumar

Titel

First GPR119 PET Imaging Ligand: Synthesis, Radiochemistry, and Preliminary Evaluations

Ist Teil von

• Journal of medicinal chemistry, 2023-07, Vol.66 (13), p.9120-9129

Ort / Verlag

United States: American Chemical Society

Erscheinungsjahr

2023

Quelle

MEDLINE

Beschreibungen/Notizen

• G-protein-coupled receptor 119 (GPR119) has emerged as a promising target for treating type 2 diabetes mellitus. Activating GPR119 improves glucose homeostasis, while suppressing appetite and weight gain. Measuring GPR119 levels in vivo could significantly advance GPR119-based drug development strategies including target engagement, occupancy, and distribution studies. To date, no positron emission tomography (PET) ligands are available to image GPR119. In this paper, we report the synthesis, radiolabeling, and preliminary biological evaluations of a novel PET radiotracer [18F]­KSS3 to image GPR119. PET imaging will provide information on GPR119 changes with diabetic glycemic loads and the efficacy of GPR119 agonists as antidiabetic drugs. Our results demonstrate [18F]­KSS3’s high radiochemical purity, specific activity, cellular uptake, and in vivo and ex vivo uptake in pancreas, liver, and gut regions, with high GPR119 expression. Cell pretreatment with nonradioactive KSS3, rodent PET imaging, biodistribution, and autoradiography studies showed significant blocking in the pancreas showing [18F]­KSS3’s high specificity.